F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.
Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships.
Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a fully-fledged clinical-stage, international business. The company’s pipeline of promising bispecific antibodies has the potential to address the growing need for, and commercial opportunity from, more efficacious therapies for cancer patients. I am excited to join the management team of this next-generation immunotherapy business.”
Eliot Forster, CEO of F-star, said: “We believe Darlene’s strong commercial and capital markets experience from within the life sciences sector will play a critical role in our transition and I’m delighted that she has joined the company. Tolga’s expertise and company knowledge continues to be vital to our success as we work towards realising our ambition to bring new drugs to cancer patients as quickly as we can.”
To support F-star’s international expansion strategy, the company has also established US operations based in Cambridge, MA. Research operations will continue at the company’s site in Cambridge, UK, while the US office will support the growth of F-star’s in-house financial, clinical and regulatory activities.
F-star has also appointed Lindsey Trickett as Vice President of Investor Relations and Communications. Lindsey brings with her a wealth of experience in investor relations and antibody drug development. She joins F-star from Intellia Therapeutics, Inc., where she served as a Vice President of Investor Relations. Previously, Lindsey held senior IR and strategic marketing positions at AstraZeneca plc and spent over a decade in roles of increasing responsibility at MedImmune, LLC/AstraZeneca plc.
Both Darlene and Lindsey will be based out of F-star’s US office.
- ENDS -
About F-star Therapeutics Ltd
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for cancer patients.
For investor enquiries:
VP Investor Relations & Communications
+1 240 543 7970
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
For media enquiries
+44 (0)1223 948 094
+44 (0)7392 080 279
Catherine London, US President
Tel: +1 917-763-2709
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Western Union and France’s La Banque Postale Expand Global Digital Payments28.1.2020 13:59:00 EET | Press release
La Banque Postale, the banking subsidiary of France’s postal services’ operator, La Poste Group and one of France’s major banking networks with 10.3 million active customers today announced - as payment agent of Western Union - the expansion of global digital payment services, powered by Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments. The integration of Western Union’s global cross-border, cross-currency digital money movement platform within La Banque Postale’s mobile app and website will enable more than seven million online registered La Banque Postale customers to access Western Union’s international payment services and experience. La Banque Postale’s customers have the choice to fund their payments within the app or website using bank card and pay-out at Western Union’s Global Retail and Wallet Network. Western Union’s cross-border, cross-currency money movement platform – including global settlement capabilities, network, complianc
B2Broker Secures its Position as a PoP Liquidity Provider with Devexperts dxTrade28.1.2020 13:13:00 EET | Press release
B2Broker, a leading liquidity and technology provider of solutions to the Forex and crypto industry, has signed an agreement with Devexperts, a financial software developer, to license their dxTrade platform. dxTrade is a multi-asset trading solution for brokers which, unlike other existing OTC trading platforms, supports the entire spectrum of assets. This feature will allow B2Broker to become the leading Prime of Prime liquidity provider in the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005354/en/ B2Broker Secures its Position as a PoP Liquidity Provider with Devexperts dxTrade (Photo: Business Wire) B2Broker’s pool of trading platforms currently includes OneZero Hub, PrimeXM xCore, several MT4 and MT5 trading platforms, together with B2Trader (the company’s own Matching Engine platform). With the addition of dxTrade, clients will be able to gain quick and easy access to one of the deepest liquidity poo
ADVA to play key role in OPENQKD project pioneering market-ready quantum-safe communications28.1.2020 11:00:00 EET | Press release
ADVA (FSE: ADV) today announced that its FSP 3000 and FSP 150 platforms will play a pivotal role in the OPENQKD project. Leveraging its ConnectGuard™ technology, ADVA will provide optical and Ethernet encryptors as well as open line systems for multiple testbed locations. Funded by the European Commission, OPENQKD will create and trial a secure communication network across Europe based on quantum key distribution (QKD). The aim of the initiative is to accelerate the commercial adoption of QKD technology and to promote interoperability through an ecosystem of 38 partners, including academic institutions, network operators, and manufacturers of network and QKD equipment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005034/en/ ADVA's ConnectGuard™ technology is at the forefront of the OPENQKD project (Photo: Business Wire) “By bringing our technology and expertise to the OPENQKD project, we’re helping to address vital s
Lung Cancer Study Shows Barriers in Patient Access to Care in Europe28.1.2020 10:00:00 EET | Press release
MSD, tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today presents preliminary results from a study carried out by The Economist Intelligence Unit (The EIU) on lung cancer, which show a fragmented policy approach across Europe. The study underlines that awareness needs to be addressed on multiple fronts to fight the stigma associated with this disease and to ensure patients receive timely access to the best possible care. The data were presented days before the European Commission’s official launch of the stakeholders’ consultation on Europe’s Beating Cancer Plan. “There is no room for complacency in lung cancer; 1 out of 5 of all cancer deaths in Europe is caused by lung cancer and it kills as many Europeans as breast, colon and prostate cancer combined. The study uncovers actionable solutions to empower countries and their health systems to better manage lung cancer, and ultimately, improve the lives of people living with a diagnosis of this treatable disease,” co
Teijin to Establish Teijin Automotive Center Europe to Expand Conceptual, Designing, Prototype and Evaluation Capabilities28.1.2020 04:31:00 EET | Press release
Teijin Limited announced today that it would establish Teijin Automotive Center Europe GmbH (TACE) in Wuppertal, Germany in February as a new base for technical functions within the company’s automotive composite business. The company will handle concept, designing, prototyping, evaluations, marketing and technical research for next-generation automotive components, utilizing the Teijin Group’s capabilities to provide multi-material solutions for next-generation vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005758/en/ Envisioned demonstration and CAE experiments to be performed at TACE (Photo: Business Wire) TACE will enable Teijin to strengthen and advance its solution capabilities by establishing a strong platform for collaboration within the Teijin Group’s European automotive composite bases. It is expected to speed up concept, designing, prototyping and the evaluation of technological proposals developed
Rare Disease CDKL5 Deficiency Disorder Granted WHO Disease Classification27.1.2020 21:32:00 EET | Press release
The rare genetic disease CDKL5 Deficiency Disorder (CDD) has been designated with a new disease code in the International Classification of Diseases (ICD), the medical classification list from the World Health Organization (WHO). The CDKL5 Deficiency Disorder diagnostic code will be incorporated in the October 1, 2020 classification revision. The medical classification, currently in its tenth revision (ICD-10), uses a list of alphanumeric codes to document a person’s medical condition. For example, a person with migraine headaches will receive the G43 code, and a person with type 2 diabetes the E11 code. These codes are then used for clinical research and care, and increasingly also for health insurance billing and reimbursement. According to the WHO, about 70% of the world’s health expenditures are allocated using ICD codes for reimbursement and resource allocation. There are many medical conditions that do not have a code in the international medical classification, and these disease
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom